TherapeuticsMD Inc
$ 2.23
-0.45%
16 Jan - close price
- Market Cap 25,810,800 USD
- Current Price $ 2.23
- High / Low $ 2.37 / 2.18
- Stock P/E 223.00
- Book Value 2.37
- EPS 0.01
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE N/A %
- 52 Week High 2.37
- 52 Week Low 0.72
About
TherapeuticsMD, Inc. is an innovative women's healthcare company headquartered in Boca Raton, Florida, dedicated to advancing hormone therapy and contraception through its unique prescription medications. With a strong emphasis on research and development, the company has established an impressive pipeline aimed at addressing critical unmet medical needs in women's health. TherapeuticsMD's commitment to enhancing the quality of life for women at various life stages positions it as a leader in delivering transformative health solutions, underlining its significant role within the broader healthcare ecosystem.
Analyst Target Price
$5.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-11-12 | 2024-08-12 | 2024-05-10 | 2024-03-29 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-27 |
| Reported EPS | 0 | 0.05 | 0.0219 | 0.0219 | -0.0528 | -0.0945 | -0.0766 | -0.08 | -0.32 | -0.24 | -0.37 | 8.23 |
| Estimated EPS | 0 | 0 | None | 0.04 | 0.04 | 0.03 | 0.03 | -0.13 | -0.05 | -0.07 | 0.06 | -1.11 |
| Surprise | 0 | 0.05 | 0 | -0.0181 | -0.0928 | -0.1245 | -0.1066 | 0.05 | -0.27 | -0.17 | -0.43 | 9.34 |
| Surprise Percentage | None% | None% | None% | -45.25% | -232% | -415% | -355.3333% | 38.4615% | -540% | -242.8571% | -716.6667% | 841.4414% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TXMD
2026-01-06 12:09:45
This article reports on TherapeuticsMD's Q3 2025 financial results. Details regarding revenue, expenses, and net income for the quarter would be provided, offering insights into the company's financial performance and operational highlights.
2026-01-06 07:09:45
Lundin Law PC has announced a securities class action lawsuit against TherapeuticsMD, Inc. (NYSE MKT: TXMD) for alleged violations of federal securities laws between July 7, 2016, and April 9, 2017. The lawsuit claims that TherapeuticsMD made misleading statements and failed to disclose deficiencies in its New Drug Application for TX-004HR, which likely caused a delay in FDA approval and subsequently harmed investors. The firm is encouraging investors who suffered losses during this period to contact them before the June 19, 2017 lead plaintiff motion deadline.
2025-12-30 15:09:09
TherapeuticsMD Inc. (TXMD) stock fell by 3.4%, underperforming the broader market. This report also mentions Unity Software's (U.US) fourth-quarter financial results, which exceeded revenue estimates but reported a loss per share. The content implies that the dip in TherapeuticsMD's stock is a separate event being reported alongside other market news.
2025-12-23 01:09:02
TherapeuticsMD Inc. (TXMD) stock outperformed its competitors on a strong trading day, as reported by MarketWatch. This article also briefly mentions Unity Software's (U.US) fourth-quarter financial results, which exceeded revenue estimates but reported a loss per share.
2025-12-03 04:42:27
TherapeuticsMD Inc. (TXMD) saw its stock price drop by 3.9%, underperforming the broader market. This news was released concurrently with Unity Software's (U.US) fourth-quarter earnings report, which showed significant revenue growth but also a quarterly loss per share.
2025-12-03 04:42:27
TherapeuticsMD Inc. (TXMD) stock underperformed its competitors on Monday, according to a report by MarketWatch. The article also briefly mentions Unity Software's (U.US) fourth-quarter financial results, noting a revenue increase of 35% year-over-year to $609 million and a quarterly loss of 66 cents per share.
